Health insurance giant Cigna is putting real money behind artificial intelligence in its pharmacy business.
According to Reuters, Cigna has invested $100 million in a new AI-powered specialty pharmacy program.
Specialty pharmacy is the corner of the drug business that handles complex, often expensive medications — the kind used to treat conditions like cancer, rheumatoid arthritis, and multiple sclerosis. These drugs frequently require special handling, close monitoring, and careful coordination between patients, doctors, and insurers. It is also one of the fastest-growing and costliest areas of prescription spending.
The Reuters report frames the move as Cigna building a new program powered by AI, backed by a $100 million commitment. Beyond the headline figure and the focus on specialty pharmacy, further specifics were not detailed in the source.
The investment signals how one of the largest players in American health insurance is looking to AI as a tool inside the machinery that decides how high-cost drugs get delivered and managed.
Why it matters: When a company the size of Cigna wires $100 million into AI for the most expensive slice of the drug system, it is a sign that automated decision-making is moving closer to the medications millions of patients depend on — with real stakes for cost, access, and care.